Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B:A Multicenter Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seung Up | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Lee, Han Ah | - |
dc.contributor.author | Kim, Mi Na | - |
dc.contributor.author | Lee, Eun Ju | - |
dc.contributor.author | Shin, Hye Jung | - |
dc.contributor.author | Lee, Yu Rim | - |
dc.contributor.author | Lee', Hye Won | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.contributor.author | Han, Kwang-Hyub | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Kweon, Young Oh | - |
dc.contributor.author | Kim, Beom Kyung | - |
dc.contributor.author | Park, Soo Young | - |
dc.date.available | 2020-11-10T06:48:59Z | - |
dc.date.issued | 2020-04 | - |
dc.identifier.issn | 1055-9965 | - |
dc.identifier.issn | 1538-7755 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/28180 | - |
dc.description.abstract | Background: Long-term antiviral therapy (AVT) for chronic hepatitis B (CHB) reduces the risk of hepatocellular carcinoma (HCC). We assessed the temporal trends in the incidence of HCC over time during long-term AVT among Asian patients with CHB. Methods: Patients with CHB receiving entecavir/tenofovir (ETV/TDF) as a first-line antiviral were recruited from four academic hospitals in the Republic of Korea. We compared the incidence of HCC during and after the first 5 years of ETV/TDF treatment. Results: Among 3,156 patients, the median age was 49.6 years and males predominated (62.4%). During the follow-up, 9.0% developed HCC. The annual incidence of HCC per 100 person years during the first 5 years (n = 1,671) and after the first 5 years (n = 1,485) was statistically similar (1.93% vs. 2.27%, P = 0.347). When the study population was stratified according to HCC prediction model, that is, modified PAGE-B score, the annual incidence of HCC was 0.11% versus 0.39% in the low-risk group (<8 points), 1.26% versus 1.82% in the intermediate-risk group (9-12 points), and 4.63% versus 5.24% in the high-risk group (>= 13 points; all P > 0.05). A Poisson regression analysis indicated that the duration of AVT did not significantly affect the overall trend of the incidence of HCC (adjusted annual incidence rate ratio = 0.85; 95% confidence interval, 0.66-1.11; P = 0.232). Conclusions: Despite long-term AVT, the risk of HCC steadily persists over time among patients with CHB in the Republic of Korea, in whom HBV genotype C2 predominates. Impact: Careful HCC surveillance is still essential. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | American Association for Cancer Research | - |
dc.title | Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B:A Multicenter Study | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1158/1055-9965.EPI-19-0614 | - |
dc.identifier.scopusid | 2-s2.0-85082754484 | - |
dc.identifier.wosid | 000539995800018 | - |
dc.identifier.bibliographicCitation | Cancer Epidemiology Biomarkers and Prevention, v.29, no.4, pp 832 - 837 | - |
dc.citation.title | Cancer Epidemiology Biomarkers and Prevention | - |
dc.citation.volume | 29 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 832 | - |
dc.citation.endPage | 837 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Public, Environmental & Occupational Health | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Public, Environmental & Occupational Health | - |
dc.subject.keywordPlus | PRACTICE GUIDELINES MANAGEMENT | - |
dc.subject.keywordPlus | VIRUS-INFECTION | - |
dc.subject.keywordPlus | LIVER FIBROSIS | - |
dc.subject.keywordPlus | MARKERS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.